Mrs. Cyndi Lou Miller, LPN, ASN, ADN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 82022 S 4739 Rd, Stilwell, OK 74960 Phone: 918-575-5991 |
Joie Smith, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: Rr 6 Box 840, Stilwell, OK 74960 Phone: 918-696-8826 Fax: 918-696-8840 |
Georgia Delain Lowe, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: Route 6 Number 840, Stilwell, OK 74960 Phone: 918-696-8800 |
Augusta Reed, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: Rr 6 Box 840, Stilwell, OK 74960 Phone: 918-696-8800 |
News Archive
For children with a common middle-ear problem, a simple procedure with a nasal balloon can reduce the impact of hearing loss and avoid unnecessary and ineffective use of antibiotics, according to a new study led by researchers from the University of Southampton.
Hubris is the greatest danger in wealthy countries -; a sort of smug assumption that advanced technologies and emergency-preparedness plans guarantee that Ebola and other germs will not spread. It was hubris that left Toronto's top hospitals battling SARS in 2003, long after the virus was conquered in poorer Vietnam. It was hubris that led the World Health Assembly in 2013 to cut the WHO's outbreak-response budget in favor of more programs to treat cancer and heart disease.
The largest randomized trial involving smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of myeloma symptoms, according to Mayo Clinic researchers.
The doctor instructed his patient to stand in front of him. He cupped her crotch and inserted his fingers into her vagina through her clothes, moving his hand repeatedly to her rectal area. Then he squeezed her breasts, according to a formal accusation filed by the Medical Board of California.
This week, Lancet Oncology reports results of a 1,093-person phase III clinical trial of the drug necitumumab (IMC-11F8) combined with chemotherapies gemcitabine and cisplatin against stage IV squamous non-small cell lung cancer. With addition of necitumumab, median overall survival was 11.5 months compared with median survival of 9.9 months with the two chemotherapies alone.
› Verified 6 days ago